| abstract |
Human insulin analogues having a positively charged amino acidnresidue, i.e. Lys or Arg, in position B28, i.e. in position 8nin the B-chain calculated from [Gly B20 ], and optionally beingnfurther modified in the C-terminal end of the B-chain fromn[Phe B24 ] to the C-terminal amino acid residue and optionally A21nand/or B3 being different from Asn as well as insulinnpreparations containing the human insulin analogues arenprovided. |